KR102646764B1 - 질환 및 장애의 치료 및 방지를 위한 단쇄 지방산의 용도 - Google Patents

질환 및 장애의 치료 및 방지를 위한 단쇄 지방산의 용도 Download PDF

Info

Publication number
KR102646764B1
KR102646764B1 KR1020197024459A KR20197024459A KR102646764B1 KR 102646764 B1 KR102646764 B1 KR 102646764B1 KR 1020197024459 A KR1020197024459 A KR 1020197024459A KR 20197024459 A KR20197024459 A KR 20197024459A KR 102646764 B1 KR102646764 B1 KR 102646764B1
Authority
KR
South Korea
Prior art keywords
scfa
acid
composition
disease
agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197024459A
Other languages
English (en)
Korean (ko)
Other versions
KR20190108144A (ko
Inventor
이라 씨. 스펙터
마크 에이. 페이텔슨
알라 아르주마냔
Original Assignee
템플 유니버시티-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션
이라 씨. 스펙터
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 템플 유니버시티-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션, 이라 씨. 스펙터 filed Critical 템플 유니버시티-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션
Publication of KR20190108144A publication Critical patent/KR20190108144A/ko
Application granted granted Critical
Publication of KR102646764B1 publication Critical patent/KR102646764B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Transplantation (AREA)
KR1020197024459A 2017-01-27 2018-01-26 질환 및 장애의 치료 및 방지를 위한 단쇄 지방산의 용도 Active KR102646764B1 (ko)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US201762451192P 2017-01-27 2017-01-27
US62/451,192 2017-01-27
US201762510867P 2017-05-25 2017-05-25
US201762510872P 2017-05-25 2017-05-25
US62/510,867 2017-05-25
US62/510,872 2017-05-25
US201762530371P 2017-07-10 2017-07-10
US62/530,371 2017-07-10
US201762539572P 2017-08-01 2017-08-01
US62/539,572 2017-08-01
US201762588961P 2017-11-21 2017-11-21
US62/588,961 2017-11-21
PCT/US2018/015383 WO2018140687A1 (en) 2017-01-27 2018-01-26 Use of short chain fatty acids for the treatment and prevention of diseases and disorders

Publications (2)

Publication Number Publication Date
KR20190108144A KR20190108144A (ko) 2019-09-23
KR102646764B1 true KR102646764B1 (ko) 2024-03-13

Family

ID=62978768

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197024459A Active KR102646764B1 (ko) 2017-01-27 2018-01-26 질환 및 장애의 치료 및 방지를 위한 단쇄 지방산의 용도

Country Status (5)

Country Link
US (3) US20220142978A1 (https=)
JP (3) JP7161731B2 (https=)
KR (1) KR102646764B1 (https=)
CN (1) CN110475551A (https=)
WO (1) WO2018140687A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10588871B1 (en) 2019-06-28 2020-03-17 Nexzol Pharma, Inc. Transdermal formulation for the treatment of pain and/or inflammation
WO2021216548A1 (en) * 2020-04-21 2021-10-28 University Of Massachusetts Methods and compositions for treatment of age-related macular degeneration
FR3111551B1 (fr) * 2020-06-19 2022-08-26 Oreal Composition gélifiée comprenant un sel d’acide gras à chaîne courte
CN111632047A (zh) * 2020-07-27 2020-09-08 上海市中医医院 木犀草素在预防和治疗子宫内膜异位症药物中的应用
US20240009154A1 (en) * 2020-08-04 2024-01-11 Temple University-Of The Commonwealth System Of Higher Education Methods and compositions for treating cytokine release syndrome
JP2023549522A (ja) * 2020-11-12 2023-11-27 テンプル・ユニバーシティ－オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション がん予防における短鎖脂肪酸の使用
JP2024518421A (ja) * 2021-05-07 2024-05-01 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム キメラ抗原受容体（ｃａｒ）ｔ細胞治療に関連する血清メタボロミクス
CN114767685B (zh) * 2022-04-25 2023-10-20 北京大学第三医院（北京大学第三临床医学院） 四氢叶酸在抑菌或者预防或治疗眼部疾病中的用途
GB202208911D0 (en) * 2022-06-17 2022-08-10 Ravan Bio Limtied Treatments
CN115068457A (zh) * 2022-07-04 2022-09-20 南昌大学第一附属医院 短链脂肪酸在制备治疗急性胰腺炎药物中的应用
WO2024100756A1 (ja) * 2022-11-08 2024-05-16 ミヤリサン製薬株式会社 子宮、卵管および卵巣における炎症の予防および／または治療剤
FR3141616A1 (fr) * 2022-11-09 2024-05-10 Pll Therapeutics Principes actifs et leur utilisation pour rétablir la perméabilité intestinale et/ou prévenir ou lutter contre des maladies multifactorielles
KR20250107214A (ko) * 2022-11-10 2025-07-11 템플 유니버시티-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 간질환 또는 간장애의 치료 또는 예방 방법
WO2024151503A1 (en) * 2023-01-11 2024-07-18 Temple University- Of The Commonwealth System Of Higher Education Treatment of skin disorders with short chain fatty acids
CN116687899B (zh) * 2023-07-10 2025-03-21 河北医科大学第二医院 短链脂肪酸钠盐丁酸钠和丙酸钠组合用药在als治疗中的应用
US12102611B2 (en) * 2024-03-25 2024-10-01 Olfactive Biosolutions, LLC Compositions and methods for treating hypertension by modulating endocrine activity
US12226383B1 (en) 2024-04-30 2025-02-18 Velocity Life Sciences, LLC Compositions containing short-chain fatty acid, methods of use, and methods of making thereof
CN120093748B (zh) * 2025-03-26 2026-02-06 江汉大学 包含异戊酸和仑伐替尼的组合物在制备抗癌药物中的应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080107646A1 (en) * 2002-04-26 2008-05-08 Yih-Lin Chung Method for ameliorating pruritus
WO2008079697A2 (en) * 2006-12-20 2008-07-03 Bausch & Lomb Incorporated Method of treating mucin deficiency with an active pharmaceutical and related composition
US20130115280A1 (en) * 2010-07-29 2013-05-09 Cosmo Technologies Ltd Pharmaceutical and/or dietary compositions based on sort chain fatty acids
WO2015006355A2 (en) * 2013-07-09 2015-01-15 Puretech Ventures, Llc Compositions containing combinations of bioactive molecules derived from microbiota for treatment of disease

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4735967A (en) * 1985-05-28 1988-04-05 Neesby Torben E Method for desensitizing the gastrointestinal tract from food allergies
JP2000072667A (ja) 1998-08-25 2000-03-07 Kurasuraa:Kk 大腸炎治療用経口投与剤
CN101959429B (zh) * 2008-01-08 2014-09-10 阿克塞利亚制药公司 抗微生物肽系统的激动剂
US9339667B2 (en) * 2009-02-18 2016-05-17 Sea Qiq As Mixture of inorganic compounds, preparations containing the mixture and use of the mixture
US8962686B2 (en) * 2010-04-28 2015-02-24 The Chinese University Of Hong Kong Method and medication for prevention and treatment of ocular hypertension and glaucoma
EP2389932A1 (en) * 2010-05-28 2011-11-30 Lunamed AG Compositions for use in genetic disorders comprising 4-phenyl-butyric acid and its salts
WO2012131069A1 (en) 2011-03-31 2012-10-04 Proponent Biotech Gmbh Short chain fatty acids and their derivatives for use in treatment immunogenic disorders
WO2014022886A1 (en) * 2012-08-08 2014-02-13 Fischer Karen Jane A method, use, and dietary supplement composition for at least treating an atopic or non-atopic disorder in a patient
US10092541B2 (en) * 2014-08-15 2018-10-09 Celgene Corporation Methods for the treatment of diseases ameliorated by PDE4 inhibition using dosage titration of apremilast

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080107646A1 (en) * 2002-04-26 2008-05-08 Yih-Lin Chung Method for ameliorating pruritus
WO2008079697A2 (en) * 2006-12-20 2008-07-03 Bausch & Lomb Incorporated Method of treating mucin deficiency with an active pharmaceutical and related composition
US20130115280A1 (en) * 2010-07-29 2013-05-09 Cosmo Technologies Ltd Pharmaceutical and/or dietary compositions based on sort chain fatty acids
WO2015006355A2 (en) * 2013-07-09 2015-01-15 Puretech Ventures, Llc Compositions containing combinations of bioactive molecules derived from microbiota for treatment of disease

Also Published As

Publication number Publication date
KR20190108144A (ko) 2019-09-23
CN110475551A (zh) 2019-11-19
JP2020505471A (ja) 2020-02-20
JP7688360B2 (ja) 2025-06-04
US20250017883A1 (en) 2025-01-16
WO2018140687A1 (en) 2018-08-02
JP7161731B2 (ja) 2022-10-27
US20250099410A1 (en) 2025-03-27
JP2022179617A (ja) 2022-12-02
US20220142978A1 (en) 2022-05-12
JP2025069304A (ja) 2025-04-30

Similar Documents

Publication Publication Date Title
JP7688360B2 (ja) 疾患及び障害の処置及び予防のための短鎖脂肪酸の使用
US11759442B2 (en) Use of short chain fatty acids for the treatment and prevention of diseases and disorders
US20240342122A1 (en) Use of Short Chain Fatty Acids in Cancer Prevention
KR20220129001A (ko) 치료제의 표적 전달을 위한 조작된 혈소판
CN104884065B (zh) 治疗癌症的方法
JP6464084B2 (ja) 排出阻害剤およびこれを用いる治療法
KR20160066554A (ko) 브루톤 타이로신 키나제 억제제 및 면역요법을 이용한 치료
MD3864003T2 (ro) Modulatori de promedicamente ai căii integrate de răspuns la stres
CA3050553A1 (en) Therapeutic modifiers of the reverse mode of atp synthase
AU2019208238A1 (en) Therapeutic Modifiers of the Reverse Mode of ATP Synthase
JP2024513575A (ja) Ｆｇｆｒ阻害剤及びネクチン－４標的化剤を含む併用療法
KR20180095586A (ko) 난소암 치료를 위한 hdac 억제제와 항-pd-l1 항체의 조합
WO2023114445A1 (en) Prevention of bone loss
JP2022500485A (ja) グラピプラント単位剤形
WO2015085351A1 (en) Pharmaconutrient composition
WO2023141119A1 (en) Bacterial compositions and methods for treating cancer and immune diseases
KR20180088401A (ko) 3-(5-아미노-2-메틸-4-옥소-4h-퀴나졸린-3-일)-피페리딘-2,6-다이온을 사용한 주기 요법
EP3573612A1 (en) Use of short chain fatty acids for the treatment and prevention of diseases and disorders
JP2025538212A (ja) 肝疾患又は障害を治療若しくは予防する方法
ES2953032T3 (es) Métodos ex vivo para la activación de las células inmunológicas
HK40082664A (en) Use of short chain fatty acids in cancer prevention

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601